CVN-293 is under clinical development by Cerevance and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CVN-293’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CVN-293 overview

CVN-293 is under development for the treatment of  Alzheimer's disease and amyotrophic lateral sclerosis. It acts by targeting potassium channel subfamily K member 13 (KCNK13).It is being developed based on Nuclear Enriched Transcript Sort sequencing (NETSseq) platform. It is administered by oral route.

Cerevance overview

Cerevance is a pharmaceutical company that strives to develop medicines for the treatment of neurological and psychiatric diseases. It is also developing preclinical and clinical programs for Parkinson’s disease, L-Dopa induced dyskinesia, cognitive impairment, neuroinflammation, and anxiety. The company harnesses its technology platform to reveal the molecular properties of each brain cell type in human tissue. Cerevance aims to develop new therapies targeting antibodies, small molecules, and other modalities. It is also measuring glial cells across the brain which plays a role in diseases involving neuro-inflammation. The company has presence in the US and the UK. Cerevance is headquartered in Boston, Massachusetts, the US.

For a complete picture of CVN-293’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.